Tel Aviv’s Nasus Pharma Names CFO Ahead of Planned NS002 Study

Tel Aviv-based Nasus Pharma announced Nir Sassi's appointment as chief financial officer on November 16. The appointment took effect on November 11, as the company prepares a planned Phase 3 study of its NS002 drug candidate. The study timetable remains a plan, not a clinical result.
Nasus lists its headquarters at 65 Yigal Alon Street. The announcement is a development in a local drug-development business, relevant to readers following the city's life-sciences sector. It does not announce a new service for residents or a way to obtain the product.
A change in the finance team
The company's filing with the US Securities and Exchange Commission records the appointment and says Sassi previously served as chief financial officer at Indaptus Therapeutics and, before that, Intec Pharma. It identifies him as an Israeli certified public accountant with an economics and accounting degree from Ben-Gurion University.
The distinction between taking office and announcing it matters. The fresh development is the November 16 disclosure, not a claim that Sassi joined this morning. The announcement does not set out an additional local recruitment drive or new vacancies for the public.
What Nasus plans to study
On its product page, Nasus describes NS002 as an epinephrine powder candidate delivered through the nose, under development for anaphylaxis, a severe allergic reaction. The company is pursuing another way of administering the drug. That development aim does not establish all the benefits it hopes to demonstrate.
In the appointment announcement, Nasus reiterates plans to begin its pivotal Phase 3 study in the fourth quarter of 2026 and report initial results in the first quarter of 2027. These are future milestones. A management appointment does not show that the study has started, succeeded or secured marketing approval.
Separate the next milestones
Nasus had already reported in September that the FDA cleared it to initiate a clinical study of NS002. Permission to conduct a study is a development step, not a product launch. Future updates should be read separately for an actual study start, reported results and regulatory decisions.
The current disclosure adds a name to the leadership team and restates the company's plans. It is not a reason to replace prescribed treatment or assume a new alternative is available at a pharmacy. For local readers, this is an organizational step at a Tel Aviv drug developer; its medical progress will need to be judged against the evidence published next.



